This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Glycogen synthase deficiency / GSD type 0 / GYS2 deficiency / Hepatic aglycogenosis글리코젠합성효소결핍

Contents and key points
ItemDetails
A. Classification codesICD-10: E74.0 | Special Copayment Reduction: V117
B. SynonymsGlycogen synthase deficiency, GSD type 0, Hepatic glycogen synthase deficiency, GYS2 deficiency, Hepatic aglycogenosis, glycogen storage disease type 0
C. Adult onsetPossible first onset in adulthood: not low — mostly diagnosed in infancy to childhood with fasting hypoglycemia and ketonemia, but in carriers of mild variants, fasting hypoglycemia after puberty may be mild, and cases of diagnosis delayed until adulthood have been reported. In some cases, hyperglycemia in adulthood (impaired postprandial glucose handling) is first detected as a diabetes-like finding.
1. History1963: first described by Lewis et al. → 1980s–90s: pathophysiology elucidated → 1992: GYS2 gene cloned → since the 2000s: spread of molecular diagnosis → efficacy of dietary therapy established.
2. CausesGYS2 gene mutation → liver glycogen synthase (LGS) deficiency → inability to synthesize hepatic glycogen after meals → fasting hypoglycemia (with ketosis) + postprandial hyperglycemia. Autosomal recessive. Muscle glycogen synthase (GYS1) and the cardiac form (GYS1) are separate genes.
3. GeneticsGYS2: 12p12.1, 16 exons. Missense, nonsense, splicing and small deletion/insertion variants reported. Muscle GSD type 0 is a separate disease caused by GYS1 (19q13.3) mutations. An ultra-rare disease reported in only about 50 families worldwide.
4. General epidemiologySo rare that the exact prevalence is unknown. Fewer than about 50 families reported worldwide. Although named 'type 0' in the GSD classification, it is an unusual reverse GSD in which glycogen is deficient (not in excess). Very few reports in Korea.
5. PathophysiologyLGS deficiency → inability to convert glucose → glycogen in the liver after meals → postprandial hyperglycemia (inability to store glucose) + fasting hypoglycemia (rapid depletion because there is no glycogen store) + fasting ketonemia (compensatory lipolysis). A distinctive dual pattern of 'fasting ketotic hypoglycemia + postprandial hyperglycemia'.
6. SymptomsFasting hypoglycemia (seizures, decreased consciousness, lethargy) and ketonemia. Postprandial hyperglycemia. Growth retardation. Recurrent fasting ketoacidosis. Long-term complications: effects on neurodevelopment, risk of brain damage with recurrent hypoglycemia.
7. SignsFasting ketonemia and hypoglycemia. Liver of normal size (no hepatomegaly because there is no glycogen accumulation — an important distinguishing point from other GSDs). Postprandial hyperglycemia. Low blood insulin (when fasting). Elevated ketone bodies.
8. ScreeningSuspected in infants and children with a pattern of fasting ketonemia + hypoglycemia. Normal liver size (no hepatomegaly) is a clue distinguishing it from other GSDs. Postprandial blood glucose monitoring (confirming postprandial hyperglycemia). GYS2 gene analysis.
9. DiagnosisFasting hypoglycemia + elevated ketone bodies + postprandial hyperglycemia. Liver biopsy: glycogen deficiency (PAS negative or very weak). Reduced LGS enzyme activity (fresh liver tissue or leukocytes). GYS2 gene analysis. On glucose tolerance testing, excessive rise in blood glucose followed by delayed decline.
10. TreatmentFrequent meals (high-carbohydrate, low-fat) to minimize fasting time. Uncooked cornstarch (at night). Restriction of simple sugars (to prevent postprandial hyperglycemia). Acute ketoacidosis: intravenous glucose. Prevention of long-term complications: prevention of recurrent hypoglycemia. No specific drug therapy.
11. PrognosisWith adherence to dietary therapy, growth and development can normalize. Risk of effects on neurodevelopment if recurrent hypoglycemia is not prevented. Liver complications are rare because there is no hepatomegaly or cirrhosis. Control of hypoglycemia and hyperglycemia in adulthood determines long-term prognosis.
12. PreventionEducation on frequent meals, nighttime uncooked cornstarch, strict limitation of fasting time, early recognition of ketonemia, genetic counseling and genetic testing of family members.
13. ReferencesWeinstein DA et al. J Inherit Metab Dis 2006 and 9 other references

1. History

Glycogen synthase deficiency (GSD type 0) was first described in 1963 by Lewis and colleagues. They histologically confirmed that hepatic glycogen was markedly reduced in pediatric patients with fasting ketonemia and recurrent hypoglycemia and presumed this to be a disorder of glycogen synthesis. At the time, the reverse phenotype, in which glycogen is actually deficient, unlike other GSDs in which hepatic glycogen accumulates in excess, was regarded as highly unusual.

From 1966 into the 1970s, Stadlman, Stumpf and colleagues confirmed by enzyme assays that liver glycogen synthase (LGS) activity is reduced in this disease. This established GSD caused by glycogen deficiency (shortage), rather than glycogen accumulation (excess), as an independent disease, and it was named 'type 0', preceding the existing GSD I–V classification.

In 1988, Burchell and colleagues characterized the biochemical properties of the GYS2 protein in detail, and in 1992 the human GYS2 gene (12p12.1) was cloned. As molecular genetic confirmation subsequently became possible, various pathogenic variants were identified in several families. The disease is very rare worldwide, reported to date in fewer than about 50 families, and reports in Korea are also very few.

Since the 2000s, dietary therapy using uncooked cornstarch has been shown to be effective in preventing nocturnal hypoglycemia, and clinical experience has accumulated that restricting simple sugars after meals helps reduce postprandial hyperglycemia. In 2006, Weinstein and colleagues comprehensively reviewed the clinical, biochemical and genetic characteristics of GSD type 0 and proposed guidelines for diagnosis and management. Muscle GSD type 0 (GYS1 deficiency) is a disease caused by variants in the separate GYS1 gene (19q13.3), with cardiomyopathy and exercise intolerance as the main symptoms, and shows a clinical phenotype different from GYS2 deficiency.


2. Causes

Glycogen synthase deficiency (GSD type 0) is an autosomal recessive genetic disease caused by deficiency or loss of function of liver glycogen synthase (LGS) due to pathogenic variants in the GYS2 gene. LGS is the key enzyme that synthesizes glycogen by adding glucose residues from UDP-glucose to the glycogen chain via α-1,4 linkages. When this enzyme is deficient, glucose absorbed after meals cannot be stored as hepatic glycogen and remains in the blood, causing postprandial hyperglycemia.

There are three isoenzymes of glycogen synthase. ① Liver form (LGS, GYS2) — liver-specific expression, GYS2 gene (12p12.1). ② Muscle/cardiac form (GYS1) — expressed in skeletal muscle, myocardium and brain, GYS1 gene (19q13.3). The liver form of GSD type 0 is GYS2 deficiency, and the muscle form (GYS1 deficiency) is a separate rare disease that mainly shows cardiomyopathy and exercise intolerance.

LGS activity is activated by postprandial insulin secretion (insulin → inhibition of glycogen synthase kinase → LGS dephosphorylation → activation) and inhibited by fasting glucagon. When LGS is deficient in GSD type 0, this regulatory pathway itself becomes nonfunctional, resulting in a dual metabolic disorder of ① inability to store glucose after meals and ② depletion of available hepatic glycogen during fasting.

The mode of inheritance is autosomal recessive, and children of two carrier parents are affected with a 25% probability. About 30 pathogenic GYS2 variants have been reported to date, including missense, nonsense, splicing and small deletion/insertion variants. Because the disease is very rare worldwide (fewer than about 50 families reported), no founder effect or concentration in specific ethnic groups has been reported.


3. Genetics

The GYS2 gene is located on chromosome 12p12.1 and consists of 16 exons. The translation product is liver glycogen synthase of 703 amino acids, whose active/inactive state is regulated by serine/threonine phosphorylation. Regulation of enzyme activity is a complex system operating through both covalent modification (phosphorylation/dephosphorylation) and noncovalent modification (allosteric activation by G6P, inhibition by ATP).

Because GSD type 0 is very rare worldwide, the types of pathogenic variants reported are limited. About 30–40 unique variants have been reported to date, including missense (about 50%), nonsense (about 25%), splicing (about 15%) and small deletion/insertion (about 10%) variants. There are no reports of founder variants concentrated in specific ethnic groups, and it occurs sporadically in various ethnic groups worldwide.

Phenotype–genotype correlation: Homozygous or compound heterozygous loss-of-function variants (nonsense, frameshift) result in almost no LGS activity, with severe fasting hypoglycemia and marked ketoacidosis from infancy. When some residual LGS activity is preserved with missense variants, symptoms are mild, and diagnosis is sometimes delayed until childhood or adolescence. Clinical severity varies between individuals even with the same variant.

Muscle GSD type 0 is caused by variants in the GYS1 gene (19q13.3) and shows a completely different clinical phenotype (cardiomyopathy + exercise intolerance, no liver symptoms). GYS1 and GYS2 share about 70% gene sequence homology but differ in tissue expression specificity.

Diagnostic confirmation and genetic counseling: NGS-based analysis of the entire GYS2 gene (exons + intron boundaries + CNV) to confirm variants on both alleles is the current standard. Because noninvasive molecular diagnosis is possible, genetic analysis is recommended before liver biopsy when the diagnosis is suspected. After the familial variant is identified, carrier testing and prenatal diagnosis are performed.


4. General epidemiology

Glycogen synthase deficiency (GSD type 0) is one of the rarest subtypes of glycogen storage disease, and its exact worldwide prevalence is not known. Cases reported in the literature number fewer than about 50 families as of 2024; the actual prevalence is estimated to be much lower than this, but there may also be a considerable number of undiagnosed cases due to lack of access to diagnosis.

Unlike conventional glycogen storage diseases, GSD type 0 is characterized by 'glycogen deficiency', so its clinical phenotype (fasting hypoglycemia and ketosis + postprandial hyperglycemia + no hepatomegaly) is distinctive. Because this reverse phenotype deviates from the usual GSD screening patterns, diagnosis is often delayed. In particular, cases have been reported in which postprandial hyperglycemia is misdiagnosed as type 1 diabetes or fasting ketotic hypoglycemia is misdiagnosed as ketotic hypoglycemia.

No concentration in specific ethnic groups has been reported, and it occurs sporadically in various ethnic groups worldwide. Reports in Korea are very few, limited to cases diagnosed as rare cases at pediatric endocrinology and metabolism specialty institutions. GSD type 0 is eligible for Special Copayment Reduction (V117), and after diagnosis, rare disease registration and management centered on specialized metabolic disease centers are necessary.

GSD type 0 is not included in newborn screening, and clinical screening based on clinical symptoms (fasting ketotic hypoglycemia in infancy, postprandial hyperglycemia, no hepatomegaly) is the realistic approach. Because of the rarity of this disease, it is ideally diagnosed and managed at specialized centers with accumulated clinical knowledge.


5. Pathophysiology

The core pathophysiology of glycogen synthase deficiency (GSD type 0) is a dual metabolic disorder of inability to store glucose after meals and insufficient glucose release during fasting due to hepatic LGS deficiency. The uniqueness of this disease is that, whereas all other GSDs involve excess glycogen accumulation, GSD type 0 has the reverse phenotype in which hepatic glycogen is actually deficient.

Mechanism of postprandial hyperglycemia: When glucose is absorbed from the small intestine after a meal and blood glucose rises, insulin is secreted from the pancreas and activates LGS in the liver, storing excess glucose as glycogen. In GSD type 0 with LGS deficiency, this storage step is blocked, so glucose absorbed after meals cannot be converted to glycogen and remains in the blood, causing postprandial hyperglycemia. Blood glucose 2 hours after a meal may approach or exceed diabetic thresholds.

Mechanism of fasting hypoglycemia: The normal liver maintains blood glucose during fasting by breaking down glycogen stored after meals via phosphorylase. In GSD type 0, there is no postprandial glycogen storage, so hepatic glycogen is already depleted within 3–4 hours of fasting and hypoglycemia occurs. During prolonged fasting, gluconeogenesis operates as a compensatory mechanism, but a characteristic feature is that early decline in blood glucose occurs even with short fasting (between meals).

Mechanism of ketonemia: When insulin secretion decreases and glucagon and growth hormone secretion increase due to fasting hypoglycemia, lipolysis in adipose tissue accelerates and large amounts of free fatty acids move to the liver. In the liver, free fatty acids are converted via fatty acid oxidation to ketone bodies (acetoacetate, beta-hydroxybutyrate), which accumulate in the blood. This is the mechanism of fasting ketonemia and ketoacidosis. This ketosis is fundamentally different from GSD I (no ketosis) and is a characteristic biochemical finding of GSD type 0.

Mechanism of growth retardation: Recurrent hypoglycemia and ketoacidosis lower energy availability and reduce insulin-like growth factor (IGF-1) secretion, slowing growth velocity. Frequent metabolic episodes also affect overall nutritional status. In most cases, growth velocity normalizes when metabolism is stabilized with dietary management.

Mechanism of neurological effects: Recurrent severe hypoglycemia can cut off the supply of glucose, the brain's main energy source, causing neuronal damage. Ketone bodies can serve to some extent as an alternative energy source, but when hypoglycemia is abrupt and severe, ketone bodies alone are not sufficient. Preventing recurrent hypoglycemia through early diagnosis and thorough dietary management is essential to protect neurodevelopment.


6. Symptoms

The clinical symptoms of glycogen synthase deficiency (GSD type 0) mainly appear in infancy to childhood and are characterized by the dual pattern of fasting ketotic hypoglycemia and postprandial hyperglycemia.

Fasting hypoglycemia and ketosis: Between meals (especially during overnight fasting), blood glucose drops rapidly, causing sweating, pallor, decreased consciousness and seizures. At the same time, ketone bodies (acetone, acetoacetate, beta-hydroxybutyrate) rise in the blood and urine, accompanied by symptoms of ketonemia with an acetone odor (fruity breath). A characteristic feature, unlike GSD I, is that ketone bodies rise, which means the fatty acid oxidation mechanism is normal. In infancy, hypoglycemia occurs immediately when the interval between feedings becomes longer.

Postprandial hyperglycemia: Blood glucose rises excessively after meals (2-hour postprandial blood glucose 200 mg/dL or higher), which causes a misdiagnosis of diabetes in some patients. However, it differs from the usual diabetic pattern in that fasting blood glucose is low or normal and fasting hypoglycemia is actually more prominent. If postprandial hyperglycemia persists for a long time, HbA1c may be mildly elevated.

Growth retardation: Growth velocity sometimes decreases due to recurrent hypoglycemic episodes and chronic metabolic instability. When metabolism is stabilized through dietary management, growth velocity normalizes.

Effects on neurodevelopment: Owing to the effects of recurrent severe hypoglycemia on the brain, intellectual developmental delay, attention deficit and learning disabilities may occur. Early diagnosis and prevention of hypoglycemia can greatly improve neurodevelopmental outcomes.

No hepatomegaly: One of the most important distinguishing findings of GSD type 0. Because glycogen does not accumulate, the liver remains normal in size. Being a GSD without hepatomegaly is a clinical clue that fundamentally differs from other GSDs (I, III, IV, etc.).


7. Signs

On physical examination, the most characteristic finding in GSD type 0 is the absence of hepatomegaly. Whereas hepatomegaly is prominent almost without exception in other hepatic GSDs, liver size is normal in GSD type 0. This is because glycogen does not accumulate.

Blood and urine findings: Low blood glucose in the fasting state (less than 50 mg/dL), markedly elevated serum ketone bodies (beta-hydroxybutyrate), elevated free fatty acids, low insulin. Excessive rise in blood glucose in the postprandial state. Serum lactate is normal (an important distinction from GSD I — lactic acidosis is characteristic of GSD I). Serum uric acid is normal or mildly elevated. Liver enzymes (AST, ALT) are normal or mildly elevated. Urine ketones positive. Acetone breath (ketone breath) may be detected on physical examination.

Glucose tolerance test findings: After an oral glucose load of 1.75 g/kg, a pattern of impaired glucose tolerance with excessive rise and delayed decline in blood glucose is confirmed (postprandial hyperglycemia). At the same time, insulin secretion is normal or increased but ineffective (because hepatic glycogen synthesis itself is impossible).

Glucagon stimulation test findings: When glucagon is administered in the fasting state, there is almost no rise in blood glucose (there is no hepatic glycogen, so there is no glycogen to break down). Even in the postprandial state, the rise in blood glucose is minimal. This is similar to GSD I but is distinguished by whether ketone bodies are elevated.

Liver ultrasound and MRI: Normal liver size, decreased echogenicity (no fat deposition, no glycogen accumulation). This contrasts with the hepatomegaly and increased echogenicity in other GSDs. There are also no findings of fatty liver.


8. Screening

There is no standardized universal newborn screening test for glycogen synthase deficiency (GSD type 0). Early clinical screening based on clinical symptoms and the distinctive biochemical pattern is the realistic approach.

Clinical screening clues: GSD type 0 should be strongly suspected when the following combination is identified. ① Fasting ketotic hypoglycemia in infants and children (requires differentiation from other ketotic hypoglycemias). ② Concurrent postprandial hyperglycemia (postprandial rise in blood glucose that looks like diabetes). ③ No hepatomegaly (the key distinguishing finding from other GSDs). ④ No lactic acidosis (excluding GSD I). ⑤ Normal or mildly abnormal liver enzymes. The combination of these 5 patterns is highly specific for GSD type 0.

Blood glucose monitoring: Blood glucose and ketone bodies are measured simultaneously during fasting (8 hours or more before a meal), and blood glucose is measured 1–2 hours after meals to confirm the dual pattern of 'fasting hypoglycemia + ketonemia + postprandial hyperglycemia'. Self-monitoring with a home glucose meter and ketone meter (blood beta-hydroxybutyrate) helps screening and management.

Glucose tolerance test (OGTT): If an excessive postprandial rise in blood glucose is confirmed on the oral glucose tolerance test, differentiation of disorders of carbohydrate metabolism, including GSD type 0, is necessary. A 'dual abnormality' pattern, in which postprandial blood glucose rises markedly while fasting blood glucose is low or borderline, requires careful interpretation because it differs from ordinary diabetes or insulin resistance.

Family history-based screening: In families in which a patient with GSD type 0 has already been born, prenatal genetic diagnosis is possible in the next pregnancy. Early diagnosis of asymptomatic siblings by genetic testing and proactive dietary education are recommended.


9. Diagnosis

Glycogen synthase deficiency (GSD type 0) is confirmed by a combination of identifying the characteristic biochemical pattern, glycogen deficiency in liver tissue or measurement of LGS enzyme activity, and GYS2 gene analysis.

Biochemical diagnosis: The combination of fasting hypoglycemia + ketonemia (fasting ketosis) + normal lactate + postprandial hyperglycemia is the core biochemical pattern of GSD type 0. Fasting glucagon stimulation test: no rise in blood glucose (breakdown impossible due to hepatic glycogen deficiency). Postprandial glucagon stimulation test: minimal rise in blood glucose even 2 hours after a meal. Simultaneous measurement of insulin, C-peptide, free fatty acids and ketone bodies. Amino acid and organic acid profiles are normal, or alanine may be decreased due to gluconeogenic activity.

Liver biopsy and measurement of LGS enzyme activity: LGS enzyme activity is measured in fresh liver tissue (radioisotope or photometric method using a UDP-glucose substrate). LGS activity is markedly reduced in GSD type 0. On PAS staining of liver biopsy tissue, glycogen content is markedly reduced compared with normal liver (by about 50–80%) or nearly absent. The fact that this finding is the complete opposite of other GSDs (excess glycogen accumulation) is the key to histological confirmation. Because genetic analysis is now available, liver biopsy is performed selectively.

GYS2 gene analysis: NGS-based analysis of the entire GYS2 gene (16 exons + intron boundaries + CNV) confirms pathogenic variants on both alleles. If no variants are found, mRNA analysis (to identify large intronic variants) is added. Once molecular confirmation is made, carrier testing of family members and prenatal diagnosis are possible.

Continuous glucose monitoring (CGM): Recording the pattern of fasting hypoglycemia and postprandial hyperglycemia for 72 hours or more with a continuous glucose monitoring device can identify a characteristic fluctuation pattern (low when fasting, high after meals) that helps diagnosis. CGM is also useful for optimizing dietary management.


10. Treatment

There is no specific enzyme replacement therapy or approved drug therapy for glycogen synthase deficiency (GSD type 0), and stabilization of blood glucose through dietary therapy is the cornerstone of treatment.

Principles of dietary therapy: Two opposing goals must be achieved simultaneously. ① Prevention of fasting hypoglycemia — minimize meal intervals and provide complex carbohydrates regularly. ② Prevention of postprandial hyperglycemia — restriction of simple sugar intake (glucose, sugar, fructose, lactose), a diet centered on complex carbohydrates with a low glycemic index (GI).

Frequent meals and nighttime uncooked cornstarch: Meal intervals are kept at 2–3 hours, and uncooked cornstarch (UCCS) is taken before bedtime to prevent nocturnal hypoglycemia. Uncooked cornstarch is digested slowly and maintains blood glucose for a long time, making it effective during overnight fasting. In infants, feeding intervals are minimized, and nighttime tube glucose infusion is used if necessary.

Restriction of simple sugars: To prevent postprandial hyperglycemia, foods and beverages containing glucose, fructose, sugar and lactose are restricted. A diet centered on complex carbohydrates (whole grains, vegetables) is recommended. In a hypoglycemic emergency, glucose gel or oral glucose solution is given immediately (simple sugars are allowed only in this case).

Treatment of acute ketoacidosis: In acute ketoacidosis episodes in which oral intake is difficult, blood glucose is maintained at 70–100 mg/dL with intravenous 10% glucose infusion (6–8 mg/kg/min). If acidosis is severe, sodium bicarbonate supplementation is considered.

Use of continuous glucose monitoring (CGM): CGM is very useful for optimizing dietary management and for early warning of hypoglycemia. It detects nocturnal hypoglycemia in real time and is used to adjust the uncooked cornstarch dose and bedtime diet.

Nutrition education and regular follow-up: Establishing an individualized dietary plan through dietitian counseling, analysis of blood glucose records and education on ketone measurement are essential. Regular follow-up including regular blood glucose monitoring, growth assessment, and measurement of insulin, ketone bodies and insulin-like growth factor (IGF-1) is recommended.


11. Prognosis

The prognosis of glycogen synthase deficiency (GSD type 0) differs greatly depending on whether early diagnosis is made and the level of adherence to dietary therapy. When thorough dietary management follows early diagnosis, normal growth and development are possible and life expectancy is close to normal.

Neurodevelopmental prognosis: The effect of recurrent severe hypoglycemia on the brain is the most important prognostic factor. When early diagnosis and prevention of hypoglycemia are achieved, normal development without neurodevelopmental abnormalities is possible. Conversely, if diagnosis is delayed or recurrent hypoglycemia is not prevented, intellectual disability or learning disabilities may occur.

Growth prognosis: When metabolism is stabilized with dietary management, growth velocity normalizes and normal final height is often reached. However, with poor management, growth retardation may persist.

Liver complications: Because hepatomegaly and cirrhosis do not develop in GSD type 0, liver complications are rare. This is the biggest prognostic difference from other hepatic GSDs. There is a theoretical concern about the risk of diabetic complications (microvascular complications) if postprandial hyperglycemia is not controlled for a long time, but actual clinical reports are limited.

Management in adulthood: Dietary management is necessary in adulthood as well. Some patients feel that their symptoms have eased after puberty, but because fasting hypoglycemia and postprandial hyperglycemia persist, dietary management must be maintained. Research on the long-term effects of diabetes-like metabolic abnormalities in adulthood is lacking, so regular monitoring is necessary.


12. Prevention

Prevention of glycogen synthase deficiency (GSD type 0) centers on genetic counseling, early diagnosis and prevention of hypoglycemia through dietary therapy. In families in which a patient with GSD type 0 has already been born, the birth of an affected child can be prevented in the next pregnancy through prenatal genetic diagnosis and PGT.

Education on prevention of hypoglycemia: Patients and caregivers are thoroughly educated on ① strict maintenance of meal intervals (no fasting longer than 2–3 hours), ② taking uncooked cornstarch before bedtime, ③ early recognition of ketosis (acetone breath, lethargy, nausea), and ④ emergency glucose supplementation (emergency room visit if oral intake is impossible). Schools and childcare facilities are informed of the patient's condition and emergency response methods.

Use of continuous glucose monitoring: Use of CGM detects hypoglycemic and hyperglycemic episodes in real time, optimizing dietary management. Setting CGM alarms allows nocturnal hypoglycemia to be detected in advance.

Regular monitoring: Regular follow-up including regular measurement of blood glucose, ketone bodies, insulin, IGF-1 and HbA1c, growth assessment, neurodevelopmental assessment (infants and children) and nutritional status assessment is recommended. Glycemic control targets: ideally, fasting blood glucose of 60–100 mg/dL, 2-hour postprandial blood glucose below 140 mg/dL and HbA1c of 5.5–7.0% should be maintained.


13. References

  1. Weinstein DA, Correia CE, Saunders AC, Wolfsdorf JI. Hepatic glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia. Mol Genet Metab. 2006;87(4):284-288. DOI: 10.1016/j.ymgme.2005.10.006. PMID: 16337417.
  2. Lewis GM, Spencer-Peet J, Stewart KM. Infantile hypoglycaemia due to inherited deficiency of glycogen synthetase in liver. Arch Dis Child. 1963;38:40-48. DOI: 10.1136/adc.38.197.40. PMID: 13986399.
  3. Orho M, Bosshard NU, Buist NR, et al. Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0. J Clin Invest. 1998;102(3):507-515. DOI: 10.1172/JCI2890. PMID: 9691086.
  4. Bachrach BE, Weinstein DA, Orho-Melander M, et al. Glycogen synthase deficiency (glycogen storage disease type 0) presenting with hyperglycemia and glucosuria: report of three new mutations. J Pediatr. 2002;140(6):781-783. DOI: 10.1067/mpd.2002.124317. PMID: 12072897.
  5. Gitzelmann R, Spycher MA, Feil G, et al. Liver glycogen synthase deficiency: a rarely diagnosed entity. Eur J Pediatr. 1996;155(7):561-567. DOI: 10.1007/bf01957905. PMID: 8831078.
  6. Hoogeveen IJ, van der Ende RM, van Spronsen FJ, et al. Normoglycemic ketonemia as biochemical presentation in ketotic glycogen storage disease. JIMD Rep. 2016;28:41-47. DOI: 10.1007/8904_2015_505. PMID: 26661798.
  7. Kollberg G, Tulinius M, Gilljam T, et al. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N Engl J Med. 2007;357(15):1507-1514. DOI: 10.1056/NEJMoa066959. PMID: 17928599.
  8. Spiegel R, Mahamid J, Shalev SA, et al. Molecular characterization and genetic heterogeneity of two novel mutations in the GYS2 gene causing glycogen storage disease type 0 in three unrelated families. Eur J Med Genet. 2005;48(2):171-175. DOI: 10.1016/j.ejmg.2004.12.002. PMID: 15907466.
  9. Ozen H. Glycogen storage diseases: new perspectives. World J Gastroenterol. 2007;13(18):2541-2553. DOI: 10.3748/wjg.v13.i18.2541. PMID: 17552001.
  10. Davis MK, Weinstein DA. Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure. Pediatr Transplant. 2008;12(2):137-145. DOI: 10.1111/j.1399-3046.2007.00803.x. PMID: 18307655.